We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about dermatomyositis and the unmet needs in its treatment? (0:24)
- What is the role of IV immune globulin (IVIG) in the treatment of dermatomyositis? (1:28)
- What were the aims and design of the ProDERM study? (2:39)
- What were the findings of the study in terms of efficacy, safety and tolerability? (3:50)
- What will be the impact of these findings on clinical practice? (6:27)
Disclosures: Dr. Aggarwal has received consulting fees from various pharmaceutical companies including Octapharma, BMS, Mallinckrodt, Pfizer, Janssen, Abbvie, EMD serono, AstraZeneca, Csl Behring, Kezar, Kyverna, Agrenx, Alexion, Q32, Corbus, BI.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Jonathan Bernstein, AAAAI 2021: Final results from the HELP Study
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the findings from the HELP study, investigating lanadelumab for the prevention of hereditary angioedema (HAE) attacks. The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final […]
Jonathan Bernstein, AAAAI 2021: Hereditary Angioedema – Prevalence, Pathogenesis, and Treatment Options
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients. The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: […]
Su Lwin: Epidermolysis Bullosa and Gene Therapy (Part 2)
It was lovely to speak to our Expert Faculty member, Su Lwin (King’s College London, London, UK), about the development and clinical application of gene and cell therapy for individuals with epidermolysis bullosa. Questions Could you tell us a little about your research into spray-on gene therapy for recessive dystrophic epidermolysis bullosa? (0:18) Could you […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!